| Delta hit Israel in June, just as the country began to reap the benefits of one of the world’s fastest vaccine roll-outs |
Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.
Delta hit Israel in June, just as the country began to reap the benefits of one of the world’s fastest vaccine roll-outs.
With an open economy and most curbs scrapped, Israel went from single-digit daily infections and zero deaths to around 7,500 daily cases last week, 600 people hospitalised in serious condition and more than 150 people dying in that week alone.
On 30th July, it began administering a third dose of the Pfizer/BioNtech vaccine to people over 60, the first country to do so.
The rate of disease spread among vaccinated people aged 60 and above – known as the reproduction rate – began falling steadily around 13th August, and has dipped below one, indicating that each infected person is transmitting the virus to fewer than one other person. A reproduction rate of less than one means an outbreak is subsiding.
Scientists said booster shots are having an impact on infections, but other factors are likely contributing to the decline as well.
“The numbers are still very high but what has changed is that the very high increase in the rate of infections and severe cases has diminished, as has the pace at which the pandemic is spreading,” said Eran Segal, Data Scientist, Weizmann Institute of Science and an adviser to the government.
“This is likely due to the third booster shots, an uptake in people taking the first dose and the high number of people infected per week, possibly up to 100,000, who now have natural immunity,” Segal said.
After reaching one of the highest per-capita infection rates in the world this month, the question now is whether Israel can battle its way out of a fourth outbreak without imposing another lockdown that would damage its economy.
Evidence has emerged showing that while the vaccine is still highly effective in preventing serious illness, its protection diminishes with time. However, there is no consensus among scientists and agencies that a third dose is necessary, and the World Health Organization (WHO) has said more of the world should be vaccinated with a first dose before people receive a third dose.
The United States has announced plans to offer booster doses to all Americans, eight months after their second vaccine dose, citing data showing diminishing protection. Canada, France and Germany have also planned booster campaigns.
About a million of Israel’s 9.3 million population have so far chosen not to vaccinate at all and children under 12 are still not eligible for the shots.
According to Doron Gazit, a member of the Hebrew University’s COVID-19 expert team which advises government, the rise in cases of severely ill vaccinated people in the 60 and older group has been steadily slowing to a halt in the last 10 days.
“We attribute this to the booster shots and to more cautious behaviour recently,” Gazit said.
More than half of those over 60 have received a third jab, according to the Health Ministry.
The rate of new severe cases among unvaccinated patients aged 70 and older is now seven times that of vaccinated patients, and the gap will continue to grow as long as infections rise, according to Gazit. Among those over 50, that gap is four-fold.
“We are optimistic, but very cautious,” Nitzan Horowitz, Health Minister, Israel said. “It gives us more time, slows the spread and we’re moving away from lockdown.”
But even if the boosters are slowing the pandemic’s pace, it is unlikely to fend delta off entirely.
Dvir Aran, Biomedical Data Scientist, Technion – Israel’s Institute of Technology, said that while cases are retreating, other measures are needed alongside boosters to stop the pandemic. “It will take a long time until enough people get a third dose and until then thousands more people will be getting seriously ill.”
Since delta’s surge, Israel has reimposed indoor mask wearing, limitations on gatherings and ramped up rapid testing.
Its “living with COVID” policy will be tested come September, when schools reopen after summer break and when the Jewish holiday season starts, with families traditionally gathering to celebrate.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.
Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032
The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.
Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.